Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CCR3 | P51677 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4256865 | 0.89 | CCR3 (0.55) | ALDH1A1NPSR1CCR3 | |
| SCHEMBL4255676 | 0.87 | CCR3 (0.60) | ALDH1A1GAAKDM4ECCR3MEN1 | |
| SCHEMBL4257514 | 0.80 | ALDH1A1 (0.54) | ALDH1A1NPSR1KDM4ECHRM4 | |
| SCHEMBL28657592 | 0.77 | HDAC3 (0.73) | ALDH1A1KDM4EMEN1KMT2ACHRM4 | |
| SCHEMBL29826183 | 0.76 | KDM4E (0.52) | ALDH1A1NPSR1KDM4E | |
| SCHEMBL14814041 | 0.76 | ALDH1A1 (0.62) | ALDH1A1NPSR1KDM4EMAPK1CHRM4 | |
| SCHEMBL2980930 | 0.75 | DRD2 (0.67) | CCR3CXCR4ACHE | |
| SCHEMBL4249601 | 0.75 | CCR3 (0.62) | CCR3 | |
| SCHEMBL28642184 | 0.74 | HDAC3 (0.77) | MEN1KMT2ACHRM4ACHE | |
| SCHEMBL30798965 | 0.74 | DRD2 (0.69) | KDM4EHSD17B10CHRM4FAAHACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239860-A1 | NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1710233-A1 | NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239860-A1 | NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE | ADORA2A, ADORA2B, HTR1F | ALDH1A1 559/4885NPSR1 68/4885GAA 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.